The Ohio State University

Running trials

• Not yet recruiting

  Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

  NCT07594548· Phase 1· Source

• Not yet recruiting

  Peer Support for Family Caregivers of Older Adults Living With Dementia

  NCT07868718· Phase 2· Source

• Recruiting

  Symptoms of Polycystic Ovarian Syndrome Ameliorated by Keto-Adaptation Pilot

  NCT07227363· Source

• Recruiting

  A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety

  NCT06820723· Phase 2· Source

• Not yet recruiting

  AAV2-hAADC for Parkinson's Disease (PDCS-01)

  NCT07267065· Phase 1· Source

• Not yet recruiting

  Gestational Hypertension and Preeclampsia Blood Pressure (BP) Treatment Goals Less Than 140/90 vs. Less Than 160/110 mmHg: The GOALPOST Trial

  NCT07746271· Phase 3· Source

• Not yet recruiting

  Solving Stigma Through POV Simulation: Enhancing Pharmacist Empathy-based Practices With Sickle Cell Disease Patients

  NCT07217548· Source

• Recruiting

  Pacritinib Effectiveness in Real-world Settings

  NCT07774455· Source

• Recruiting

  The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry

  NCT07612878· Source

• Recruiting

  Self-Supervised Constraint-Induced Movement Therapy for Stroke Recovery

  NCT07723300· Source

• Recruiting

  A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression

  NCT07716098· Phase 3· Source

• Recruiting

  Pridopidine Phase 3 Study in Huntington's Disease

  NCT07609108· Phase 3· Source

• Recruiting

  Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists

  NCT07702461· Source

• Recruiting

  Parent-Mediated Telehealth Intervention for Insomnia in Young Autistic Children

  NCT07435740· Source

• Recruiting

  A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

  NCT07393282· Phase 3· Source

• Recruiting

  Study of INCA036978 in Participants With Myeloproliferative Neoplasms

  NCT07441694· Phase 1· Source

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Source

• Recruiting

  Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

  NCT07326566· Phase 2· Source

• Recruiting

  A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  NCT06769698· Phase 2· Source

• Recruiting

  Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study

  NCT07676565· Source

• Recruiting

  Stroke Volume-based Fluid Resuscitation in AP

  NCT07756476· Source

• Recruiting

  Randomized Controlled Trial of Two Mobile Health Strategies to Manage Postpartum Hypertension

  NCT07209254· Source

• Recruiting

  A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder

  NCT06696755· Phase 2· Source

• Recruiting

  Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

  NCT07224360· Phase 2· Source

• Recruiting

  Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma

  NCT07225621· Phase 2· Source

• Recruiting

  Zilucoplan for Severe gMG Exacerbations

  NCT07215949· Phase 3· Source

• Recruiting

  Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

  NCT07325292· Phase 3· Source

• Recruiting

  Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease

  NCT07378644· Phase 2/3· Source

• Recruiting

  A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

  NCT07266831· Phase 2/3· Source

• Recruiting

  Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

  NCT07195591· Phase 3· Source

• Recruiting

  A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

  NCT07276399· Phase 3· Source

• Recruiting

  A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  NCT07213674· Phase 3· Source

• Recruiting

  Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2

  NCT07225127· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Source

• Recruiting

  A Study of SGT-212 Gene Therapy in Friedreich's Ataxia

  NCT07180355· Phase 1· Source

• Recruiting

  Motor-voice Assessment in Infants (MAMI)

  NCT06807203· Source

• Recruiting

  A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

  NCT07221500· Phase 2· Source

• Active, not recruiting

  Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis

  NCT07219121· Phase 4· Source

• Active, not recruiting

  Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia

  NCT07033481· Phase 2· Source

• Recruiting

  A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

  NCT07175038· Phase 2· Source

• Recruiting

  Anti-inflammatory Activities of Vitamin C Supplementation on the Gut Barrier Function in Adults With Obesity

  NCT07151105· Source

• Recruiting

  Implementing Scalable, PAtient-centered, Team-based, Technology-enabled Care for Adults With Type 2 Diabetes (iPATH)

  NCT06251323· Source

• Recruiting

  Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  NCT07007312· Phase 3· Source

• Recruiting

  Water Competency Intervention in Autism

  NCT07076264· Source

• Active, not recruiting

  A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

  NCT07169578· Phase 3· Source

• Enrolling by invitation

  AB-1005 Long-Term Follow-up Study

  NCT07081841· Source

• Recruiting

  Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

  NCT06070012· Phase 2· Source

• Active, not recruiting

  A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)

  NCT06985147· Phase 2· Source

• Active, not recruiting

  A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

  NCT07094516· Phase 2· Source

• Recruiting

  A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

  NCT07088068· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer15 recruiting
• Head and neck cancer9 recruiting
• Alzheimer disease8 recruiting
• Childhood cancers8 recruiting
• Acute myeloid leukemia7 recruiting
• Bladder cancer7 recruiting
• Coronary artery disease7 recruiting
• Depression7 recruiting
• Prostate cancer7 recruiting
• Type 1 diabetes7 recruiting
• Melanoma6 recruiting
• Multiple myeloma6 recruiting
• Myeloproliferative neoplasms6 recruiting
• Pancreatic cancer6 recruiting
• Parkinson disease6 recruiting
• Colorectal cancer5 recruiting
• Myelodysplastic syndromes5 recruiting
• Ovarian cancer5 recruiting
• Stroke5 recruiting
• Chronic lymphocytic leukaemia4 recruiting
• Huntington's disease4 recruiting
• Sarcoma4 recruiting
• Triple-negative breast cancer4 recruiting
• Autism3 recruiting
• Diffuse large B-cell lymphoma3 recruiting
• Gastric and esophageal cancer3 recruiting
• Glioblastoma3 recruiting
• Heart failure3 recruiting
• High blood pressure3 recruiting
• HIV3 recruiting
• Sickle cell disease3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• ALS (motor neurone disease)2 recruiting
• Amyloidosis2 recruiting
• Atrial fibrillation2 recruiting
• COPD2 recruiting
• Epilepsy2 recruiting
• Follicular lymphoma2 recruiting
• Friedreich ataxia2 recruiting
• Idiopathic pulmonary fibrosis2 recruiting
• Kidney cancer2 recruiting
• Multiple sclerosis2 recruiting
• Myasthenia gravis2 recruiting
• Neuroendocrine tumours2 recruiting
• Obesity2 recruiting
• Type 2 diabetes2 recruiting
• ANCA-associated vasculitis1 recruiting
• Bipolar disorder1 recruiting
• Chronic kidney disease1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Crohn's disease1 recruiting
• Cystic fibrosis1 recruiting
• Endometrial cancer1 recruiting
• Frontotemporal dementia1 recruiting
• Lewy body dementia1 recruiting
• Liver and biliary tract cancer1 recruiting
• Macular degeneration1 recruiting
• Mantle cell lymphoma1 recruiting
• Mesothelioma1 recruiting
• Metastatic breast cancer1 recruiting
• Osteoporosis1 recruiting
• Polycystic kidney disease1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Rheumatoid arthritis1 recruiting
• Schizophrenia1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Withdrawn

  Repeated Neurocognitive Measurements in Depressed Patients

  NCT05991232· Phase 1/2· Source

• Completed

  A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease

  NCT06881836· Phase 2· Source

• Completed

  Innovative Automated Insulin Delivery System for Type 2 Diabetes

  NCT06853990· Source

• Terminated

  BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS

  NCT06704152· Phase 1/2· Source

• Completed

  A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)

  NCT06524830· Phase 2· Source

• Completed

  A Retrospective Chart Review Study of Patients With CLAD-BOS Post Lung Transplantation

  NCT06503770· Source

• Completed

  VOLT-AF IDE Clinical Study

  NCT06223789· Source

• Completed

  Feasibility and Acceptability of Incorporating Smartwatches Into an Exercise is Medicine Program in Older Individuals

  NCT06287255· Source

• Completed

  Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics

  NCT05534620· Phase 1· Source

• Recruiting

  BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT

  NCT06059638· Source

• Completed

  A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAF

  NCT06144632· Source

• Completed

  Inspiratory Muscle Training in Obese Breast Cancer Survivors

  NCT05193149· Source

• Recruiting

  A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

  NCT06022029· Phase 1· Source

• Terminated

  Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas

  NCT05580588· Phase 2· Source

• Completed

  Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention

  NCT06055036· Source

• Completed

  Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC

  NCT05510908· Source

• Completed

  RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies

  NCT05869669· Phase 2· Source

• Completed

  Respiratory Effects of E-Cigarettes in Obese Youth

  NCT05869318· Source

• Withdrawn

  Telemonitoring to Treat Group 2 Pulmonary Hypertension

  NCT04882774· Phase 2· Source

• Completed

  Re-Ablation Using a Tailored Approach Targeting EGM-Dispersion

  NCT05477147· Source

• Completed

  Mentoring to be Active for Rural Appalachia Children

  NCT05758441· Source

• Completed

  Stress and Hypertension in Dementia Caregivers

  NCT05721482· Source

• Terminated

  Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

  NCT05631574· Phase 1· Source

• Completed

  Evaluating a Web Delivered Behavioral Parent Training Intervention for Rural Parents of Children With Autism Spectrum Disorder

  NCT05554198· Source

• Completed

  A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder

  NCT05593029· Phase 2· Source

• Terminated

  Open-label Extension for Phase 3 Clinical Trials of Simufilam

  NCT05575076· Phase 3· Source

• Completed

  Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic Stroke

  NCT05585606· Phase 2· Source

• Completed

  DORAYA-HF Early Feasibility Study

  NCT05206422· Source

• Completed

  A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder

  NCT04919512· Phase 2· Source

• Completed

  A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD

  NCT05113771· Phase 2· Source

• Terminated

  Ultrafiltration Versus IV Diuretics in Worsening Heart Failure

  NCT05318105· Source

• Completed

  A Study of JNJ-55308942 in the Treatment of Bipolar Depression

  NCT05328297· Phase 2· Source

• Completed

  Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies

  NCT05225415· Phase 2· Source

• Terminated

  Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease

  NCT05352763· Phase 2· Source

• Completed

  Activity Level Monitoring Study

  NCT05379088· Source

• Completed

  AN INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY TO ASSESS THE PERFORMANCE OF THE CORDIO HEARO SYSTEM

  NCT06378632· Source

• Completed

  A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder

  NCT05067582· Phase 2· Source

• Terminated

  Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

  NCT05026177· Phase 3· Source

• Terminated

  A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD

  NCT03919162· Phase 2· Source

• Terminated

  Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

  NCT04892446· Phase 2· Source

• Completed

  Move to Improve: Telehealth Exercise to Music for HD

  NCT05270681· Source

• Completed

  Auditory Neural Function in Implanted Patients With Usher Syndrome

  NCT04906135· Source

• Completed

  Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy

  NCT04985760· Phase 1· Source

• Terminated

  A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)

  NCT04809467· Phase 1/2· Source

• Completed

  Aquatic Therapy for ASD

  NCT05092321· Source

• Completed

  AB-2004 in Treatment of Irritability Associated With Autism Spectrum Disorder (ASD)

  NCT04895215· Phase 2· Source

• Recruiting

  A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

  NCT04951622· Phase 3· Source

• Completed

  A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer

  NCT04702737· Phase 1· Source

• Completed

  Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases

  NCT04887298· Phase 1/2· Source

• Terminated

  To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

  NCT04551066· Phase 3· Source

Trial sites

• AIDS Clinical Trials Unit/The Ohio State University2 trials
• College of Nursing Ohio State University1 trial
• Ohio State University186 trials
• Ohio State University College of Medicine1 trial
• Ohio State University College of Nursing3 trials
• Ohio State University College of Pharmacy1 trial
• Ohio State University-Columbus3 trials
• Ohio State University Department Of Genetics- Site Number : 8400971 trial
• Ohio State University - Dept of Neurology1 trial
• Ohio State University /ID# 2562751 trial
• Ohio State University - Neurology3 trials
• The Ohio State University183 trials
• The Ohio State University College of Medicine2 trials
• The Ohio State University College of Nursing1 trial
• The Ohio State University, Department of Psychiatry3 trials
• The Ohio State University, Department of Psychiatry & Behavioral Health1 trial
• The Ohio State University /ID# 1250221 trial
• The Ohio State University /ID# 1454441 trial
• The Ohio State University /ID# 1598921 trial
• The Ohio State University /ID# 1647081 trial
• The Ohio State University /ID# 1647131 trial
• The Ohio State University /ID# 1694171 trial
• The Ohio State University /ID# 2005421 trial
• The Ohio State University /ID# 2075521 trial
• The Ohio State University /ID# 2110881 trial
• The Ohio State University /ID# 2150361 trial
• The Ohio State University /ID# 2174021 trial
• The Ohio State University /ID# 2178081 trial
• The Ohio State University /ID# 2215841 trial
• The Ohio State University /ID# 2304391 trial
• The Ohio State University /ID# 2367901 trial
• The Ohio State University /ID# 2655771 trial
• The Ohio State University /ID# 2675901 trial
• The Ohio State University /ID# 2713361 trial
• The Ohio State University /ID# 2713491 trial
• The Ohio State University /ID# 2729541 trial
• The Ohio State University /ID# 2747431 trial
• The Ohio State University (Site 1536)1 trial
• The Ohio State University (Site 2012)1 trial
• The Ohio State University- Site Number : 84000092 trials
• The Ohio State University- Site Number : 84000121 trial
• The Ohio State University- Site Number : 84000321 trial
• The Ohio State University- Site Number : 84000511 trial
• The Ohio State University- Site Number : 84010091 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Obesity168 works · 11 trials
• Lung cancer142 works · 29 trials
• Heart failure133 works · 18 trials
• HIV84 works · 8 trials
• Sarcoma78 works · 15 trials
• Colorectal cancer74 works · 10 trials
• Ovarian cancer71 works · 10 trials
• Melanoma69 works · 13 trials
• Epilepsy66 works · 4 trials
• Pancreatic cancer57 works · 13 trials
• Acute myeloid leukemia53 works · 20 trials
• Asthma50 works · 0 trials
• Endometrial cancer47 works · 2 trials
• Kidney cancer47 works · 8 trials
• Glioblastoma42 works · 7 trials
• Multiple myeloma42 works · 14 trials
• Triple-negative breast cancer42 works · 7 trials
• Cystic fibrosis41 works · 1 trials
• Schizophrenia38 works · 1 trials
• Head and neck cancer37 works · 22 trials
• Duchenne muscular dystrophy34 works · 0 trials
• Sickle cell disease32 works · 6 trials
• Hodgkin lymphoma30 works · 3 trials
• Cervical cancer28 works · 3 trials
• Childhood cancers27 works · 18 trials
• Lupus (SLE)24 works · 2 trials
• Autism24 works · 8 trials
• Acute lymphoblastic leukaemia24 works · 4 trials
• Bipolar disorder22 works · 2 trials
• Metastatic breast cancer22 works · 7 trials